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Renal clear cell carcinoma (CCRCC) is an aggressive tumor for which new prog-
nostic factors are needed. It has been suggested that CCRCCs co-expressing P53 
and MDM2 could represent a special subgroup; therefore the aim of this study was 
to explore their immunohistochemical features. The material studied consisted of 
470 cases of CCRCC. Immunohistochemistry for MDM2, P53, Ki-67, VEGF-A, 
VEGF-C, VEGF-D, GLUT1, CA9, and CK 7 was performed on tissue microarrays 
and assessed semi-quantitatively. On average, 6.6% or 5.3% of cases were P53+/
MDM2+, depending on the P53 antibody used. The mean percentage of Ki-67 
positive cells was 0.6% and p53-positive MDM2-positive cases showed significant-
ly higher expression of Ki-67. The other immunohistochemical parameters studied 
did not differ between p53-positive MDM2-positive cases and the rest of the sub-
types studied. Expression of almost all immunohistochemical markers differed with 
respect to pT stage; only for CA9 was the difference not significant. Furthermore, 
almost all immunohistochemical markers studied differed with respect to differenc-
es in grade; only for GLUT1 was the difference not significant. Our results suggest 
that with the exception of Ki-67, there are no significant associations between 
analyzed markers and the double P53+/MDM2+ phenotype.
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Introduction
Renal cell carcinoma (RCC) constitutes approx-
imately 9% of all human cancers. The most fre-
quent variant, conventional or clear cell (CCRCC), 
is particularly interesting because of the considerable 
progress obtained in the last few years and the intro-
duction of targeted therapy. In CCRCC patients, the 
prognosis is dependent on stage, grade and patient 
clinical condition. Other prognostic markers, includ-
ing immunohistochemistry, have been studied; how-
ever, none have been introduced into clinical practice. 
It has been suggested that co-expression of P53 and 
MDM2 may define a distinct group of CCRCCs [1]. 
In our previous work [2] we explored this hypothesis 
by comparing the histologic prognostic factors such 
as stage, grade or presence of necrosis in tumors with 
or without doubly-expressed P53 and MDM2. The 
aim of the current study is to analyze the expression 
of potential immunohistochemical markers includ-
ing Ki-67, VEGF-A, VEGF-C, VEGF-D, GLUT1, 
CK 7 and CA9 in samples expressing both P53 and 
MDM2, and to determine whether these immuno-
histochemical markers have prognostic significance.
114
Maria Hejnold, GrzeGorz dyducH, MaGdalena Białas, et al.
Material and methods
The material analyzed was retrieved from the ar-
chives of the Department of Pathomorphology. Cases 
were reviewed by an expert urologic pathologist and 
reclassified according to the most recent WHO clas-
sification [3]. For the present study, only unequivocal 
conventional (clear cell) carcinomas were chosen. The 
tumors were graded according to the International 
Society of Urological Pathologists, which is derived 
from a modification of the Fuhrman method [4]; 
this is referred to as the Fuhrman method from this 
point onward. The presence of sarcomatoid compo-
nents and necrosis was noticed, and in accordance 
with Delahunt et al. [5], another tumor grade was 
assigned that took necrosis into consideration.
For each case, a slide containing well preserved 
and representative tumor tissue was selected and 
a respective area was marked for study. Correspond-
ing blocks were used to construct a tissue microarray 
(TMA) using Tissue MicroArrayer MTA-1 (Beech-
er Instruments Inc., Sun Prairie, USA). From each 
donor block, three 0.6 mm cylinders were selected. 
The acceptor paraffin blocks were prepared noting 
the location of each cylinder, and 3 µm-thick sections 
were cut. 
For immunohistochemistry, a standard staining 
protocol was used. Briefly, the slides were dewaxed, 
rehydrated and incubated in 3% peroxide solution 
for 10 minutes to block endogenous peroxidase ac-
tivity. Antigen retrieval was carried out by microwav-
ing in citrate buffer (0.2% citric acid titrated to pH 
6.0 with 2N NaOH) 3 times for 5 minutes each at 
750 W. The primary antibodies are listed in Table 
I. The Lab Vision detection system (Thermo Fisher 
Scientific, Waltham, USA) was used. The chromogen 
used was 3-amino-9-ethylcarbazole. The slides were 
counterstained with Mayer hematoxylin (Thermo 
Fisher Scientific, Waltham, USA) and coverslipped. 
The immunohistochemistry was scored by one of the 
authors (M.H.) without knowledge of the clinico-
pathologic parameters and the results of scoring in-
troduced into an Excel spreadsheet (Microsoft Corp., 
Redmond, USA). Samples were classified as positive 
if they expressed both P53 and MDM2, and if not, 
they were marked as negative. Ki-67 expression was 
quantified based on the percentage of immunopos-
itive cells. Furthermore, to determine expression of 
each of CA9, CK 7, CD10, VEGF-A, VEGF-C, and 
VEGF-D, a scale from 0 to 3 was used, where 0 rep-
resented no staining and 3 represented strong stain-
ing of all cells. The results were averaged across all 
the scores available for the given case.
Cases lost from the TMAs were excluded from the 
study. Student’s t, χ2 and ANOVA tests were used 
where appropriate. Correlations were measured by 
Pearson’s and gamma correlation coefficients. The 
statistical analysis was done with Statistica 10 PL 
(StatSoft Inc., Tulsa, USA) and P values less than 
0.05 were considered significant.
Results
The material studied was obtained from 470 cas-
es. There were 280 (59.6%) males and 190 (40.4%) 
females. The mean age of the patients was 61.3 years 
Table I. Antibodies used in this study 
Specificity dilution manufacturer clone/type
MDM2 1 : 50 Novocastra 1B10
P53 1 : 200 DAKO DO-7
P53 1 : 50 Novocastra PAb1801
Ki-67 1 : 50 DAKO MIB-1
VEGF-A 1 : 100 Santa Cruz polyclonal A20
VEGF-C 1 : 100 Santa Cruz polyclonal H-190
VEGF-D 1 : 200 R&D systems 78923
GLUT1 1 : 50 DAKO polyclonal MYM
CK 7 1 : 50 DAKO OV-TL 12/30
CA9 1 : 100 Novocastra TH22
Table II. Immunohistochemistry results
mean median range Sd
VEGF-A 1.12 1.00 0-3.00 0.82
VEGF-C 0.76 0.67 0-2.67 0.66
VEGF-D 0.30 0.00 0-3.00 0.48
GLUT1 0.41 0.17 0-2.33 0.53
CK7 0.16 0.00 0-1.00 0.33
CA9 1.88 2.00 0-3.00 0.96
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(range 26 to 92; SD 10.59). P53 expression, when 
staining with the PAb1081 antibody, was positive 
in 62 cases (13.2%). Furthermore, when using the 
p53-specific antibody, DO-7, expression was ob-
served in 71 cases (15.1%). Reaction for MDM2 was 
positive in 178 cases (37.9%). There were 31 cases 
(6.6%) positive for both P53 and MDM2 using the 
DO-7 antibody, and 25 cases (5.3%) when using the 
PAb1081 antibody. Further details with respect to 
the histopathologic characteristics and their relation-
ship with P53 and MDM2 expression may be found 
in our previous work [2]. 
The mean percentage of Ki-67 positive cells was 
0.6% (range 0 to 33% SD 2.6). P53-positive cases 
showed significantly higher Ki-67 expression (0.24 
vs. 2.69%, p << 0.01 for DO-7 and 0.34 vs. 2.46%, 
p << 0.01 for PAb1081), yet the values for MDM2 
positive and negative cases were only slightly differ-
ent (0.52 vs. 0.66%, NS). Consequently, p53-posi-
tive MDM2-positive cases showed significantly high-
er expression (0.54 vs. 1.51%, p < 0.05 for DO-7 
and 0.44 vs. 1.97%, p < 0.02 for PAb1081). 
The results obtained when using other immuno-
histochemical stains are shown in Table II. Briefly, the 
tumors with sarcomatoid components showed lower 
expression of VEGF-A (1.15 vs. 0.69; p < 0.004) 
whereas tumors with detectable necrosis showed low-
er expression of VEGF-C (0.71 vs. 0.92; p < 0.005) 
but higher VEGF-D (0.28 vs. 0.39; p < 0.04). Some-
what surprisingly, expression of CA9 was lower in tu-
mors showing necrosis (1.98 vs. 1.45; p << 0.001). 
Almost all immunohistochemical results differed 
when considering differences in pT stage, with CA-9 
proving to be the only non-significant observation 
(Table III). Tumor diameter showed a weak correla-
tion with immunohistochemical marker expression 
(Table IV). Almost all immunohistochemical data 
differed when tumor grade was also considered (eval-
uation by both the Fuhrman and Delahunt methods 
was undertaken; see Tables V and VI). However, the 
difference observed when quantifying GLUT1 ex-
pression was not significant, although close to signif-
icance when graded according to Fuhrman. 
There was a significant difference in VEGF-A ex-
pression between P53 negative and positive cases 
(for DO-7 stain 1.17 vs. 0.86; for PAb1081 1.17 
vs. 0.87; both p < 0.001) as well as MDM2 nega-
tive and positive cases (1.05 vs. 1.25; p < 0.001). 
P53 negative and positive cases evaluated using the 
DO-7 antibody differed also in their CK7 expression 
(0.14 vs. 0.23; p < 0.05). When cases were evaluat-
ed using the PAb1081 antibody, P53 negative and 
Table III. Relationship between the immunohistochemistry results and pT stage 
vegf-a vegf-c vegf-d glut1 cK-7 ca9
mean Sd mean Sd mean Sd mean Sd mean Sd mean Sd
pT1 1.00 0.79 0.69 0.60 0.22 0.40 0.32 0.45 0.23 0.39 2.00 0.95
pT2 1.17 0.87 1.01 0.76 0.45 0.68 0.38 0.46 0.18 0.31 1.98 1.01
pT3 1.23 0.83 0.78 0.69 0.35 0.50 0.50 0.59 0.10 0.27 1.78 0.95
pT4 0.67 0.88 0.44 0.19 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00
p < 0.03 < 0.04 < 0.01 < 0.002 < 0.002 NS
Table IV. Correlations between immunohistochemistry 
and tumor diameter
diameter
VEGF-A r = 0.1389, p = 0.012
VEGF-C r = 0.0803, p = 0.147
VEGF-D r = 0.0983, p = 0.075
GLUT1 r = 0.1106, p = 0.045
CK7 r = –0.1226, p = 0.026
CA9 r = –0.1721, p = 0.002
Table V. Relationship between the immunohistochemistry results and grading by the standard method
vegf-a vegf-c vegf-d glut1 cK-7 ca9
grade mean Sd mean Sd mean Sd mean Sd mean Sd mean Sd
1 0.83 0.70 0.53 0.53 0.15 0.30 0.35 0.54 0.23 0.37 2.19 0.88
2 1.16 0.76 0.75 0.68 0.29 0.46 0.36 0.49 0.14 0.32 1.87 0.97
3 1.59 0.86 1.06 0.70 0.50 0.60 0.50 0.55 0.10 0.28 1.48 0.91
4 0.78 0.73 0.77 0.61 0.35 0.54 0.49 0.56 0.15 0.32 1.83 1.03
p << 0.001 << 0.001 << 0.001 < 0.07 (N.S.) < 0.03 << 0.001
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positive cases differed in VEGF-C expression (0.73 
vs. 0.97; p < 0.01). The immunohistochemical pa-
rameters studied did not differ significantly between 
p53-positive MDM2-positive cases and the rest of 
the cases studied; however, Ki-67 was an exception 
(see above).
Discussion
Renal cell carcinoma constitutes just 9% of human 
cancers [6], but is of interest to both the urologist and 
the urologic pathologist, due to the fact that it is the 
most aggressive of urologic malignancies. Further-
more, significant progress has been made of late both 
in understanding its biology and improving treatment. 
Prognostication in RCC is difficult and the best estab-
lished morphologic prognostic factors include tumor 
type and stage, presence of sarcomatoid components, 
and for some subtypes, histologic grade [7]. Addition-
al prognostic biomarkers would be highly clinically 
useful; however, to date, there are only limited data 
available; therefore further studies are needed before 
they might be used in clinical practice [7, 8].
The TP53 gene is mutated in many human can-
cers, and this mutation paradoxically results in P53 
protein accumulation. A significant proportion of 
RCC cases express the P53 protein product, yet the 
TP53 mutation rate in RCC is low, suggesting anoth-
er, poorly understood mechanism for protein accu-
mulation [9]. The MDM2 gene product participates 
in the same pathway as TP53; it is the main regu-
lator of TP53 functions, and its expression is recip-
rocally controlled by a P53-dependent mechanism. 
It has been hypothesized that RCCs expressing both 
P53 and MDM2 behave in a more aggressive fashion 
[1, 10, 11]. We decided to further explore this idea 
and in our previous work [2] we found a number of 
morphologic differences between P53/MDM2-posi-
tive and -negative CCRCC, which could influence the 
prognosis of this subgroup of tumors.
The basic carcinogenic mechanism in CCRCC in-
volves abnormal activation of the so-called “hypoxia 
pathway”. Furthermore, the most frequent cytoge-
netic event, a 3p deletion, leads to loss of the VHL 
gene. The VHL protein product is responsible for 
inactivating hypoxia inducible factor (HIF). Both in 
response to hypoxia and the loss of the VHL gene, 
HIF begins to fulfill its role as a transcription factor, 
leading to the expression of a number of genes. The 
protein products of these genes participate in both 
protecting the cell against hypoxia and activating an-
giogenesis. Among the genes in question there are 
carbonic anhydrase 9, vascular endothelial growth 
factors and their receptors, glucose transporter 1 and 
others [12-16]. 
Carbonic anhydrase 9 (CA9), like the other car-
bonic anhydrases, catalyzes the reversible hydration 
of carbon dioxide. This enzyme is not expressed in 
non-neoplastic kidney cells, and in several cancers 
CA9 has been shown to be a marker of hypoxia. Liao 
et al. [17] described the immunohistochemistry for 
CA9 as highly specific for CCRCC, and since then 
it has been used for diagnostic purposes. Genega et 
al. [18] studied CA9 expression in a large, heteroge-
neous group of renal tumors and confirmed that its 
expression is significantly more common in CCRCC, 
and in this tumor type is associated with the histo-
logic grade. Sandlund et al. [19] analyzed the CA9 
expression in different renal carcinomas, confirming 
its relative specificity for CCRCC. They failed to find 
a correlation between CA9 expression, tumor stage 
and grade, yet observed that tumors with low CA9 
expression behave in a considerably more aggressive 
fashion and this effect was evident also in multivariate 
analysis. On the other hand, some of the most recent 
papers have failed to show the prognostic significance 
of CA9 [20, 21]. Zerati et al. [20] analyzed a group 
of non-metastatic RCCs, and found no relationship 
between CA9 and overall survival, tumor stage, size, 
invasiveness or vascular invasion. Zhang et al. [21] 
analyzed a large cohort of RCC cases with periods of 
observation exceeding 10 years. They found that low 
CA9 expression is predictive of poor prognosis in uni-
variate analysis, both in terms of survival and time to 
metastasis, yet this effect disappeared when adjusted 
for nuclear grade and necrosis. The discordance in 
these results has been explained by comparing dif-
ferences among the different groups of patients an-
alyzed (i.e. entire CCRCC population vs. metastatic 
cases), differences in the size of the populations under 
Table VI. Relationship between the immunohistochemistry results and grading by the Delahunt [5] method
vegf-a vegf-c vegf-d glut1 cK-7 ca9
grade mean Sd mean Sd mean Sd mean Sd mean Sd mean Sd
1 0.98 0.74 0.63 0.61 0.22 0.39 0.37 0.52 0.19 0.35 2.06 0.92
2 1.50 0.88 0.99 0.73 0.43 0.59 0.41 0.48 0.10 0.28 1.55 0.96
3 1.52 0.84 1.05 0.66 0.46 0.58 0.53 0.58 0.08 0.23 1.22 0.83
4 0.71 0.73 0.78 0.65 0.37 0.55 0.50 0.56 0.18 0.34 1.99 0.98
p << 0.001 << 0.001 < 0.001 NS < 0.05 << 0.001
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study or which technology was used (i.e. TMAs vs. 
whole sections). In our study, we observed that CA9 
expression was inversely associated with tumor size, 
stage and grade. The lower CA9 expression in the 
cases where necrosis was evident may be due to the 
fact that CA9 regulation in CCRCC is not related to 
hypoxia itself, but to autonomous activation of the 
hypoxia pathway, characteristic for this cancer. Lastly, 
CA9 has also been proposed as a predictive marker 
in CCRCC. Atkins et al. [22] analyzed the influence 
of CA9 expression on immunologic treatment and 
concluded that only patients with tumors expressing 
high CA9 levels could benefit with prolonged surviv-
al after treatment with interleukin-2. More recently, 
Choueiri et al. [23] analyzed a group of metastasizing 
RCCs for CA9 expression. They concluded that al-
though CA9 is not a prognostic factor in this particu-
lar subgroup of patients, it may serve as a predictor of 
treatment results with anti-angiogenic drugs. 
Different vascular endothelial growth factors 
(VEGFs) participate in the development of blood ves-
sels and lymphatic vessels. Of these, VEGF-A is the 
main regulator of blood vessel growth and differenti-
ation. In CCRCC it is thought to act, in concert with 
its receptor, as the main autocrine stimulating loop 
for cancer cells. Following the understanding of this 
fact, antiangiogenic treatment for advanced CCRCC 
was developed. Furthermore, VEGF-A and its recep-
tor VEGFR1 are the most important of the VEGF 
family when considering molecular pathogenesis in 
RCC. Accordingly, Gunningham et al. [24] failed to 
show upregulation of VEGF-C mRNA in CCRCC. 
They also observed no increase of VEGFR2 or VEG-
FR3, but reported a significant correlation between 
levels of VEGF-C and VEGFR3. In accordance with 
our previous discussion above, Lakovlev et al. [25] 
found a positive correlation between VEGF-A expres-
sion and tumor grade, when adjusted for the expres-
sion in normal renal medullary tissue. Furthermore, 
they also found an inverse association between mi-
crovascular density and survival, when adjusted sim-
ilarly for expression in normal renal medullary tissue. 
Jacobsen et al. [26] observed a correlation between 
VEGF-A expression and survival, but only when an-
alyzed with a univariate model. Baldewijns et al. [27] 
showed that CCRCC has only limited lymphangio-
genic potential, and in fact were able to show that the 
density of lymphatic vessels was lower in cancer tis-
sue when compared with non-neoplastic kidney tis-
sue. Likewise, while the VEGF-A and C mRNA level 
were higher in cancer samples, VEGF-D mRNA level 
was higher in normal tissue. Interestingly, VEGF-D 
expression was quite low in comparison with other 
VEGF types in the samples studied during our in-
vestigation. Klatte et al. constructed a molecular 
prognostic model that included expression of Ki-67, 
VEGFR-1, VEGF-D and p53. This model showed 
higher power in predicting disease-free survival than 
standard systems, and when incorporating the stan-
dard clinicopathological data, correctly predicted the 
outcome in over 90% of cases [8]. 
Glucose transporter 1 (GLUT1) facilitates glucose 
transport across the cellular membrane, and is respon-
sible for basic intracellular glucose uptake [28]. It has 
been shown that hypoxia induces GLUT1 expression. 
Abnormal HIF activation, such as the one seen in 
CCRCC, may cause the same effect [12]. Lidgren et 
al. [29] have shown that most cases of CCRCC ex-
press high levels of GLUT1. Interestingly, in contrast 
to papillary RCC, they found no correlation between 
GLUT1 expression and tumor stage. This contrasts 
with data obtained in the present study in that we 
observed a weak, yet significant, correlation between 
this marker and tumor diameter. Lidgren et al. ob-
served low GLUT1 expression and determined that it 
was a favorable prognostic indicator both in papillary 
and clear cell RCC. Another interesting relationship 
was reported by Singer et al. [30], who found an in-
verse correlation between GLUT1 expression levels 
and effector T-lymphocyte activity. Therefore, hypox-
ia itself or activation of the hypoxia pathway might 
contribute to tumor-permitting immunosuppression.
Cytokeratin 7 (CK7) has a firmly established role 
as a diagnostic marker in renal tumor histopatholo-
gy, especially because of its distinct staining pattern 
which is characteristic for chromophobe carcinoma 
[13, 31]. Only a subset (10-15%) of CCRCCs express 
CK7, and according to some reports, this expression 
may have an influence on prognosis. Mertz et al. [32] 
analyzed the expression of both CK7 and CK19. The 
CK7 and CK19 positive tumors tended to show few-
er cytogenetic alterations and patients had a better 
prognosis. The significance of this observation was 
also noted when evaluating CK7 expression using 
multivariate analysis. Likewise, in our material, CK7 
expression was seen in lower stage, lower grade tu-
mors. 
As a proliferative marker, Ki-67 appears to be an 
obvious prognostic factor, yet several studies have 
failed to confirm this in multivariate models. In the 
study by Kramer et al., [33] Ki-67 expression was 
found to have an influence on survival, but this was 
seen only when univariate analysis was employed, 
whereas in multivariate models, the stage was the 
only variable of prognostic importance. The cit-
ed study analyzed a relatively small group of cases; 
and further, the material studied contained samples 
that were not only from clear cell carcinomas, but 
also other subtypes, which may have influenced the 
results. The results obtained by Cheville et al. [34] 
were more conclusive in that they analyzed a uni-
form group of pT1 CCRCCs and found that Ki-67 
expression was significantly higher in the tumors that 
proved fatal, but the difference disappeared when ad-
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justed for stage, grade and presence of necrosis. In 
contrast, Tollefson et al. [35] specifically addressed 
the relationship between Ki-67 expression and ne-
crosis, and came to the conclusion that although 
a correlation between the two was present, they both 
contributed more strongly as independent read-outs 
of prognosis. The prognostic significance was also ap-
parent when these data were evaluated using a mul-
tivariate model which took into account stage, grade 
and clinicopathologic parameters. Kankuri et al. [36] 
reported that tumors expressing both P53 and Ki-
67 showed higher frequency of metastases. They also 
observed, similar to our study, an association between 
P53 and Ki-67 expression. On the other hand, Moch 
et al. reported that Ki-67 expression appeared to be 
related to survival; however, when evaluated using 
a multivariate model, only the influence of P53 and 
stage remained significant [37].
In conclusion, we have analyzed a number of po-
tential prognostic markers in the context of P53 and 
MDM2 double expression in renal clear cell carcino-
ma. Our results suggest that, with the exception of 
Ki-67, there are no significant associations between 
the markers evaluated and P53+/MDM2+ pheno-
type.
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